Nutritional Holdings Limited Overview
Nutritional Holdings Limited is a small South African investment holding company. It was built around Nutritional Foods (Pty) Ltd, a fortified staple dry-food maker in Klerksdorp whose business traces back to 1947. The group sold maize-based porridges, soya mince, beverages and instant meals to institutional and mass-market customers. From 2016 it tried several diversifications: Kairos Nutrition (infant feeding), Venlai Strategic Solutions (renewable energy and security distribution), and from late 2019 cannabis through Ukusekela Holdings. Ukusekela's cannabis-extract "Ultimate Immune Booster" drove the group's first reported profit in seven years (FY2020), alongside very large announced export supply contracts. That pivot then ran into a series of governance failures:
-
a qualified audit opinion;
-
loss of control over the food subsidiary;
-
results that were restated;
-
frequent changes of finance directors;
-
liquidation proceedings brought by a former director.
These events led to JSE suspension in May 2021 and termination of the listing in December 2022. Today the company is an unlisted entity whose operating status has not been disclosed.
Company's own description. Before it was suspended, the company described itself in its listing particulars as an investment holding company. Its interests covered the manufacture, marketing and distribution of staple dry foods, cannabis infusions, oils, extracts and related edibles [S5]. Earlier handbook entries described a mass-market food business with recognised brands in the LSM 3–6 consumer segment, diversified by product, geography and urban/rural spread. The company argued that the capital cost of replicating its factory was a barrier to entry [S1]. The last reviewed interim report (H1 FY2021) organised the group into two operating activities: Foods and Cannabis [S6].
Independent characterisation. In practice the group was a single-factory food processor whose revenue never exceeded about R43 million a year in the five audited years from FY2016 to FY2020 [S1]. Losses before FY2020 were funded mainly by shareholder loans [S6]. The cannabis business started as a management agreement under which Nutritional Holdings managed Ukusekela Holdings for its own profit and loss while the acquisition was pending [S7]. The acquisition took effect on 1 October 2020 [S6]. Revenue from this business was reported as "Services" in the segment note [S6].
Business and revenue model.
Strategy
Stated strategy (paraphrased from company disclosures).
-
2016 diversification: The board concluded that a small AltX food company could not raise the capital needed to compete with established food manufacturers. It chose to diversify into the industrial and manufacturing sectors through reverse listings of assets held by Ontario Private Equity, starting with VSS [S11].
-
2019–2020 cannabis pivot and five-year plan: Manage and then acquire Ukusekela; distribute CBD products through European and African pharmaceutical partners; position the group as a leader in South Africa's regulated cannabis industry [S6, S7]. Media coverage reported a target mix of about 70% food and 30% cannabis [S18].
-
FY2020 "Action Plan":
-
kiosks across African regional markets, backed by e-commerce;
-
instant-meal supply to the Gulf region (above R250 million a year);
-
forecast Ultimate Immune Booster sales of R83 million over six months;
-
cannabis-infused instant meals for oncology patients [S7].
-
-
2021 portfolio reset: Dispose of Nutritional Foods as non-core and use the proceeds to fund Ukusekela's growth [S30, S33].
-
2022 rebuild: Under a written commitment from a group of new investors, keep both Nutritional Foods and Ukusekela, recommission the Klerksdorp plant, reconstitute the board with experienced South African independent directors, and complete the overdue audits on a roadmap agreed with the JSE [S38, S40].
-
Post-delisting intention: Bring the financial statements up to date, reverse the liquidation, protect the underlying assets, and consider a new listing on the JSE or another South African exchange [S46, S47].
Initiatives in the last 24 months (October 2024 – October 2026): None publicly disclosed.
Medium-term targets and guidance: No quantified financial targets beyond the FY2020 Action Plan forecasts. None of those forecasts appears in any audited results.
ESG and cost programmes: In FY2020 the company said it had cut administrative costs and cash burn and redirected marketing and R&D spending to higher-return programmes [S7]. No quantified targets were given.
Products & Services
Foods (Nutritional Foods (Pty) Ltd, Klerksdorp).
Packaging ranges from 50 kg bulk bags to 30 g single-serve sachets. The plant holds ISO 22000 accreditation and complies with HACCP and GMP standards [S15]. Product rows are drawn from [S15] (FY2015 profile) and [S6, S7] (2020–2021).
Nutrition and diversified acquisitions.
Cannabis (Ukusekela Holdings).
None of the cannabis products above has disclosed specifications, registration status with the South African Health Products Regulatory Authority (SAHPRA), or audited revenue beyond the FY2020 and H1 FY2021 segment figures.
Product Portfolio
| Product line | Description / capability | Target customer | Launch / version | Pricing disclosed |
|---|---|---|---|---|
Fortified maize-based porridges | Extruded fortified staple, produced on twin-screw extrusion lines | Industrial catering; mass market LSM 3–6 | — | No |
Soya mince (textured vegetable protein) | Extruded TVP | Industrial catering; retail | — | No |
Powdered soft drinks | Dry-blended beverages | Industrial catering; retail | — | No |
Isotonic drinks | Dry-blend sports and rehydration drinks | Industrial; sport | — | No |
Gravies, spices and coatings | Savoury blends | Catering ingredients | — | No |
Milk powder blends and creamers | Dairy blends | Catering; retail | — | No |
"Twin pouch" meal replacement | Meal-replacement format for heavy industry and mining | Mining and heavy industry | Described as new in 2015 | No |
Instant High Energy Meal | Instant meal; planned to be made at the Durban head office under the Nutritional Holdings brand | Schools, correctional facilities, army bases, sports facilities, NGOs/NPOs | Highlighted 2020–2021 | No |
Instant Rehydrate | Rehydration product | Camping and outdoor, sport, remote medical kits, army, NGOs | Highlighted 2020–2021 | No |
Instant meals for the Gulf region | Proposed supply contract above R250 million a year, through existing relationships of the then CEO | Gulf-region buyers | Announced Sept 2020; never evidenced in published results | No |
“—” = not publicly disclosed.
| Offering | Description | Source |
|---|---|---|
Kairos Nutrition infant feeds | Infant feed supplied under contracts to fight malnutrition; run by registered dietician Michelle Bristow | [S10] |
VSS energy and security solutions | Accredited distributor of Bosch renewable energy and security solutions to commercial and industrial clients | [S11] |
| Product | Description | Target / channel | Pricing / volume disclosed | Source |
|---|---|---|---|---|
The Ultimate Immune Booster with Cannabis Extract | Flagship product; produced with a proprietary infusion process attributed to founder N. Dasarath | South African retail; Germany via GIH Distributors | First delivery of 72,000 units worth about R32 million, implying roughly R444 per unit (derived). Contract volumes of 50,000 units a month in year 1, rising to 200,000 a month by year 3. | [S6, S21, S22] |
CBD Body Balm | CBD topical | Japan and Asia via Grovenor Supplements FZCO, Ajman (UAE) | Part of a R776.1 million, 24-month off-take | [S6] |
CBD oils and infused products | Supplied under an off-take with Europharm Medical Corporation | European distribution in more than 15 countries (claimed) | — | [S6] |
Medical cannabis edibles (oncology) | Cannabis-infused instant meals for cancer and terminally ill patients; samples planned for September 2020 | Oncology practitioners | Company-estimated market of R500 million a year in Africa and R2.5 billion globally | [S7] |
CBD pet care | Reported as a development area | Pet owners | — | [S18] |
CO2 extraction (Indiva Pharma) | Supercritical CO2 cannabinoid extraction facility | Internal and B2B extraction | Acquisition unwound in 2022 | [S6, S38] |
Retail kiosks and e-commerce | Planned kiosks in regional markets across Africa, with online back-end and nationwide delivery | Consumers | Not implemented, as far as published reporting shows | [S7] |
“—” = not publicly disclosed.
Financial Narrative
Scope. The five most recent audited years are FY2016 to FY2020. FY2021 and FY2022 were never published [S46], and FY2023 to FY2026 are not publicly disclosed. FY2016–FY2020 data come from Profile's Stock Exchange Handbook [S1], cross-checked against SENS results [S6, S8]. Derived figures are labelled. Blank cells are not publicly disclosed.
Income statement
Notes on the income statement:
Not publicly disclosed: gross profit, EBITDA (depreciation and amortisation not available), and diluted EPS beyond basic (reported as identical where shown).
FY2019 operating loss: ZAR -3,617k per the SENS interim comparative [S8]. Profile records ZAR -3,776k [S1]. The SENS figure reconciles exactly to the reported pre-tax loss of ZAR -5,402k.
FY2020 headline figures: the short-form FY2020 announcement gave turnover of ZAR 41,729k, profit of ZAR 7,473k and EPS of 0.05c [S7]. The audited comparatives later printed in the reviewed restated interims show turnover of ZAR 40,829k, profit of ZAR 5,941k and EPS of 0.04c [S6].
FY2017 loss per share: the trading statement guided basic loss per share of 0.471–0.503c and headline loss per share of 0.227–0.259c [S13]. Profile's HEPS of -0.24c falls within that range.
Dividends: no distributions are recorded in any reviewed source. The board said in 2021 that it was "reviewing" its dividend policy [S6].
Revenue CAGR FY2016–FY2020: 1.6% a year (derived).
Cumulative net loss FY2016–FY2019: ZAR -41,629k (derived).
Commentary. Revenue stayed between R38 million and R43 million throughout, so the business never broke out of micro-cap scale. The trough came in FY2017 (operating margin -34.4%), when management cited extremely difficult trading conditions in staple dry foods [S12].
The FY2020 "turnaround" needs careful reading:
-
Group operating profit was only ZAR 1,285k.
-
After finance costs of ZAR 1,842k, the group made a pre-tax loss of ZAR 557k.
-
The reported net profit of ZAR 5,941k came entirely from a deferred-tax credit of ZAR 6,498k [S6].
-
On a pre-tax basis, FY2020 was the fifth consecutive loss-making year.
-
The improvement in segment terms came from Services (management-agreement income of ZAR 5,552k pre-tax), which offset a Foods pre-tax loss of ZAR 6,109k [S6].
Interim periods (latest available)
Source: [S6]. The columns are three views of two periods: H1 FY2020 (six months to 31 August 2019) and H1 FY2021 (six months to 31 August 2020), first as published on 14 December 2020 and then as restated on 9 June 2021.
ShareData Online records the restated interim with attributable income of ZAR -1.1 million and consolidation-adjusted EPS of 1.00c [S4]. That conflicts with the +ZAR 5,967k profit in the SENS document [S6]. The difference is not explained in the reviewed sources.
Balance sheet
FY2020 detail (audited, ZAR 000) [S6]:
Notes on the balance sheet:
-
The FY2020 total of ZAR 48,021k matches the audited balance sheet exactly [S6].
-
Net debt for FY2016–FY2019 is approximate because Profile rounds the debt-to-equity ratio to two decimals. The FY2020 figure is computed directly from the balance sheet.
-
The FY2020 short-form announcement gave FY2019 NAV per share as 1.31c [S7], against Profile's 1.73c [S1].
-
The statement of changes in equity shows an accumulated loss of ZAR -146,427k [S6], against ZAR -147,426k in the balance sheet. The ZAR 999k inconsistency appears in the source itself.
-
Treasury shares carried at ZAR 6,741k correspond to 90 million shares, the gap between 13,743,368k issued and 13,653,368k net of treasury (derived).
Commentary.
-
Equity fell from ZAR 40.2 million (FY2016) to ZAR 13.9 million (FY2018) as losses accumulated.
-
The accumulated deficit of about R147 million at FY2020, against R159.6 million of contributed capital, shows that most capital raised since listing had been lost.
-
Equity rose from ZAR 13,854k to ZAR 17,946k in FY2019 despite a ZAR 5,402k loss. That implies about ZAR 9.5 million of equity movements other than earnings, such as share issues or revaluations (derived). Their composition is not disclosed in the reviewed sources.
-
Funding came almost entirely from shareholder loans, which grew to ZAR 17.8 million at FY2020 and ZAR 20.1 million at August 2020 [S6]. A former director later went to court over one such loan of R9,449,137 [S40].
-
The FY2020 balance sheet relied on a ZAR 6.5 million deferred tax asset. For a company with five straight pre-tax losses, recognising that asset is open to question.
Cash flow
Source: [S6]. Cash flow data before FY2020 are not publicly disclosed in the reviewed sources. The restated H1 FY2021 statement repeats ZAR -602k as net investing cash flow, which looks like a presentation error in the source.
Commentary. Operating cash flow was negative in every disclosed period, including the period of the reported cannabis "profits". Profit was not turning into cash. Group cash at August 2020 was ZAR 165k (restated) [S6], and the business depended on new shareholder loans to keep going.
Ratios
Sources: ROE, current ratio and D:E from Profile [S1]; the rest derived.
Ratios not available:
ROIC and net debt to EBITDA: EBITDA is not disclosed.
Cash conversion cycle: cost of sales is not disclosed.
Receivable days: derived only for FY2020, at about 124 days (ZAR 13,923k ÷ ZAR 40,829k × 365). That is a long collection period for a food processor.
Commentary.
-
Interest cover was below 1.0x in every year.
-
FY2020's 25.5% ROE comes from the tax credit. On a pre-tax basis ROE was negative.
-
FY2018's current ratio of 0.76x marked a liquidity low point. It recovered in FY2019, consistent with the unexplained equity increase and higher shareholder loans.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Activity | Status (latest disclosed) |
|---|---|---|---|
Nutritional Holdings Limited | Parent | Investment holding | Unlisted since 19 Dec 2022; liquidation proceedings, outcome not disclosed [S46] |
Nutritional Foods (Pty) Ltd | Wholly owned subsidiary [S41] | Dry-food manufacturing, Klerksdorp [S8, S15] | Deconsolidated for loss of control (June 2021) [S6]; reconsolidation decided March 2022 [S38]; liquidation application set for February 2023 in Mahikeng [S44]; outcome not disclosed |
Ukusekela Holdings (Pty) Ltd | Wholly owned subsidiary from 1 Oct 2020 [S6, S22] | Cannabis research, infusion and products | Production on hold in April 2022 pending renewal of lapsed licences [S40] |
Kairos Nutrition (Pty) Ltd | Acquired effective 1 May 2016 [S10] | Infant feeds | Later status not publicly disclosed |
Venlai Strategic Solutions (Pty) Ltd | Acquisition effective 1 Nov 2016, subject to a profit warranty [S11] | Distribution of Bosch renewable energy and security products | Whether the deal closed or the profit warranty was met is not publicly disclosed |
Indiva Pharma LLC (business and assets) | Acquired November 2020 [S6] | CO2 cannabis extraction | Acquisition unwound (March 2022); shares to be cancelled [S38] |
Revenue by Segment and Revenue by Segment (%)
| Metric | H1 FY2020 | FY2020 | H1 FY2021 |
|---|---|---|---|
Foods external revenue (ZAR K) | 16,703 | 32,535 | 13,412 |
Services/Cannabis external revenue (ZAR K) | 0 | 8,294 | 20,312 |
Services internal revenue (ZAR K) | 300 | 300 | — |
Group revenue (ZAR K) | 16,706 | 40,829 | 33,724 |
Foods profit before tax (ZAR K) | -3,078 | -6,109 | -2,381 |
Services profit before tax (ZAR K) | -1,652 | 5,552 | 18,155 |
Foods share of group revenue (%) | 100.0 | 79.7 | 39.8 |
Services share of group revenue (%) | 0.0 | 20.3 | 60.2 |
Foods pre-tax margin (%) | -18.4 | -18.8 | -17.8 |
Services pre-tax margin (%) | — | 66.9 | 89.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (ZAR K) | 38,269 | 43,215 | 42,496 | 37,876 | 40,829 |
Revenue growth YoY (%) | — | 12.9 | -1.7 | -10.9 | 7.8 |
Operating profit/(loss) (ZAR K) | -4,692 | -14,870 | -7,263 | -3,617 | 1,285 |
Net finance costs (ZAR K) | 710 | 1,336 | 1,535 | 1,785 | 1,842 |
Profit/(loss) before tax (ZAR K) | — | — | — | -5,402 | -557 |
Income tax credit/(charge) (ZAR K) | — | — | — | 0 | 6,498 |
Net profit/(loss) attributable (ZAR K) | -5,414 | -17,031 | -13,782 | -5,402 | 5,941 |
Headline EPS (ZAR cents, pre-consolidation) | -0.16 | -0.24 | -0.31 | -0.06 | 0.04 |
Dividends per share (ZAR cents) | 0 | 0 | 0 | 0 | 0 |
Operating margin (%) | -12.26 | -34.41 | -17.09 | -9.55 | 3.15 |
Net margin (%) | -14.15 | -39.41 | -32.43 | -14.26 | 14.55 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric | H1 FY2020 | H1 FY2021 as first published | H1 FY2021 reviewed restated |
|---|---|---|---|
Revenue (ZAR K) | 16,706 | 33,724 | 20,312 |
Operating profit/(loss) (ZAR K) | -3,773 | 16,476 | 18,761 |
Net finance costs (ZAR K) | -957 | -701 | -566 |
Profit/(loss) before tax (ZAR K) | -4,730 | 15,774 | 18,195 |
Taxation (ZAR K) | 0 | -5,142 | -5,142 |
Loss on asset held for disposal (ZAR K) | 0 | 0 | -7,086 |
Net profit/(loss) (ZAR K) | -4,730 | 10,632 | 5,967 |
HEPS (ZAR cents, pre-consolidation) | -0.03 | 0.08 | 0.04 |
Total assets (ZAR K) | 39,249 | 60,717 | 47,475 |
Total equity (ZAR K) | 13,216 | 33,706 | 19,333 |
Balance Sheet and Per-Share Data (Annual)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Property, plant & equipment (ZAR K) | 24,764 | 24,730 | 23,730 | 23,214 | 22,752 |
Total current assets (ZAR K) | 9,664 | 14,035 | 8,239 | 9,643 | 17,543 |
Total equity (ZAR K) | 40,210 | 27,615 | 13,854 | 17,946 | 23,294 |
Non-current liabilities (ZAR K) | 12,616 | 15,371 | 14,334 | 17,967 | 18,194 |
Current liabilities (ZAR K) | 5,746 | 7,170 | 10,786 | 3,981 | 6,533 |
Total assets, derived as equity + liabilities (ZAR K) | 58,572 | 50,156 | 38,974 | 39,894 | 48,021 |
Working capital, derived (ZAR K) | 3,918 | 6,865 | -2,547 | 5,662 | 11,010 |
Approximate net debt, derived from Profile's D:E × equity (ZAR K) | 13,671 | 16,845 | 18,564 | 18,843 | 19,314 |
NAV per share (ZAR cents, pre-consolidation) | 1.20 | 0.80 | 0.40 | 1.73 | 2.19 |
Financial Analysis
| Line item | ZAR K |
|---|---|
Intangible assets (goodwill and intangibles) | 1,228 |
Deferred tax asset | 6,498 |
Inventories | 3,251 |
Trade and other receivables | 13,923 |
Cash and cash equivalents | 369 |
Bank overdraft | 1,199 |
Loans from shareholders (non-current) | 17,821 |
Lease liabilities (non-current) | 373 |
Lease liabilities (current) | 290 |
Trade and other payables | 5,044 |
Total debt (shareholder loans + leases + overdraft), derived | 19,683 |
Net debt, derived | 19,314 |
Share capital net of treasury shares | 159,580 |
Accumulated loss | -147,426 |
Cash Flow
| Metric | H1 FY2020 | FY2020 | H1 FY2021 restated |
|---|---|---|---|
Net cash from operating activities (ZAR K) | -1,079 | -2,197 | -602 |
Capital expenditure (ZAR K) | -1,406 | -1,564 | 0 |
Free cash flow, derived (ZAR K) | -2,485 | -3,761 | -602 |
Shareholder loans received (ZAR K) | 3,000 | 4,020 | 1,597 |
Dividends paid (ZAR K) | 0 | 0 | 0 |
Share buybacks (ZAR K) | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Return on equity (%) | -13.46 | -61.67 | -99.48 | -30.10 | 25.50 |
Return on assets, derived (%) | -9.24 | -33.96 | -35.36 | -13.54 | 12.37 |
Current ratio (x) | 1.68 | 1.96 | 0.76 | 2.40 | 2.69 |
Debt to equity, Profile net basis (x) | 0.34 | 0.61 | 1.34 | 1.05 | 0.83 |
Asset turnover, derived (x) | 0.65 | 0.86 | 1.09 | 0.95 | 0.85 |
Interest cover, operating profit ÷ net finance costs, derived (x) | -6.61 | -11.13 | -4.73 | -2.03 | 0.70 |
Disclosed or Claimed Geography Details
| Disclosed or claimed geography | Segment | Nature | Evidence status |
|---|---|---|---|
South Africa | Foods; Cannabis | Domestic manufacturing and sales; national sales channels for the Ultimate Immune Booster (claimed) | Revenue by country not disclosed [S7] |
Southern Africa | Foods | Distribution network | Qualitative only [S1] |
Germany | Cannabis | Ultimate Immune Booster via GIH Distributors (contract stated above R1 billion over 3 years) | One delivery of about R32 million announced March 2021 [S21]; not evidenced in any audited accounts |
UAE (Ajman) for Japan and Asia | Cannabis | CBD products via Grovenor Supplements FZCO (R776.1 million, 24 months) | Supply said to have started (May 2021) [S27]; not evidenced in audited accounts |
Europe (15+ countries) | Cannabis | Off-take via Europharm Medical Corporation | Qualitative only [S6] |
Gulf region | Foods | Proposed instant-meal contract above R250 million a year | Not evidenced [S7] |
Lesotho, Zimbabwe, Eswatini | Cannabis | Cultivation, manufacture and trade licences held by Ukusekela | Licences reported lapsed by April 2022 [S6, S40] |
Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Share price high (ZAR cents) | 5 | 2 | 2 | 1 | 2 |
Share price low (ZAR cents) | 1 | 1 | 1 | 1 | 1 |
Share price period end (ZAR cents) | 2 | 1 | 1 | 1 | 1 |
3-year beta | 1.73 | 2.40 | 3.71 | 1.57 | 1.06 |
Observation by Date
| Date | Observation |
|---|---|
Oct 2020 | Average 11 million shares a week, R115,246 a week (4.2% annualised turnover) |
Jan 2021 | Average 51 million shares a week, R527,490 a week (19.3% annualised turnover) |
26 May 2021 | Last possible trading day before suspension |
16 Dec 2022 | Last recorded close 25c (post-consolidation, equal to 1c before consolidation), no volume; market capitalisation R167.4 million |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E | 23.1x | Uses tax-driven net profit of ZAR 5.94 million. On a pre-tax basis the company made a loss, so P/E is not meaningful. |
P/B | 5.9x | Equity of ZAR 23.3 million |
EV/Sales | 3.8x | EV = R137.4 million + net debt of R19.3 million |
Analyst Conclusions
Management guidance. No current guidance exists. The last forward-looking statements, from December 2022, committed to:
-
bringing the financial statements up to date;
-
reversing the liquidation;
-
protecting the underlying assets, including Nutritional Foods;
-
considering a relisting once the company was regularised [S46, S47].
Consensus growth expectations. None (no analyst coverage).
Bull case.
-
Tangible asset base. The Klerksdorp extrusion plant had a carrying value of about ZAR 22.8 million at FY2020 (property, plant and equipment) [S1] and food-safety accreditation [S15]. A recapitalised owner could restart production for institutional feeding without greenfield capex.
-
Investor sponsorship. An investor group committed in writing in April 2022 to support regularisation [S40]. If the liquidation was set aside, a cleaned-up shell with two operating subsidiaries could be relisted, as the board indicated [S46].
-
Cannabis optionality. Ukusekela's licences in three Southern African jurisdictions and its branded product could regain value if renewed [S6, S40], especially as South African cannabis policy liberalises [S7].
Bear case.
-
Solvency. A final liquidation order was granted on 2 August 2022 [S43]. With no public evidence of rescission, shareholders' equity may already have been lost.
-
Earnings never independently confirmed. FY2020 profit depended on tax, the interims were restated, the audit was qualified [S6], and the large contracts never showed up in published audited revenue [S27].
-
Governance record. Repeated management turnover, related-party disposal attempts, lost subsidiary control and allegations about directors' loan security [S6, S33, S41] would make any relisting difficult.
Catalysts and monitorables (next 12 months).
Analyst verdict. Nutritional Holdings Limited is best understood as a failed micro-cap turnaround, not an investable operating company. Over the five audited years to FY2020, revenue never exceeded R43.2 million. Operating losses peaked at 34% of revenue in FY2017, and about R41.6 million of losses between FY2016 and FY2019 were funded through dilutive share issues and shareholder loans. The company's own board admitted in 2016 that it lacked the resources to compete in branded staple foods.
The 2019–2020 cannabis pivot gave the appearance of a recovery. Looked at closely, however, the FY2020 "first profit in seven years" was a pre-tax loss turned positive by a R6.5 million deferred-tax credit. The H1 FY2021 profit came from a management agreement whose 89% margin preceded actual ownership of Ukusekela. The contracts announced in 2020, worth more than R1.7 billion combined, were at least twelve times the company's market value and were concentrated in one Dubai-linked group. Audited revenue to support them was never published.
Governance then broke down step by step:
-
a qualified audit;
-
restated interims;
-
loss of control of the food subsidiary;
-
a related-party sale that collapsed;
-
four finance chiefs in about 20 months;
-
suspension, liquidation proceedings and finally delisting.
For research purposes, the entity now has the characteristics of a dormant or distressed shell. Its residual value depends on court outcomes and on the condition of the Klerksdorp plant and the cannabis licences, none of which has been reported publicly since December 2022. Any counterparty, investor or acquirer should verify CIPC status and court records first, and should treat all pre-2022 forward-looking claims, especially contract values, as unsubstantiated until audited accounts appear. Absent such evidence, the base case assumes that ordinary shareholders have little or no recoverable value.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure (as disclosed) | Background (as disclosed) |
|---|---|---|---|
G.R. Wambach | Chairman | Recorded by ShareData; appointment date not disclosed | — |
Helena Dorothea ("Althea") Grewar | Executive Director and Chair | From 1 Sep 2021; end not disclosed | CGMSA; 17 years in pharmaceuticals; more than 7 years at Certified Master Auditors (South Africa) Inc. |
Sheikh Khalfan Humaid Nasser (AKHA Belhoul / "K Nassar") | Independent non-executive Chairman, then INED from 1 Sep 2021 | Chair by 2020 to Sep 2021 | BCom and MBA (Zayed University, UAE); former UAE Ministry of Interior and police; real estate developer |
Mohammad Tariq Azum | CEO and Executive Director | In office by FY2020 (start not disclosed) to 8 Jun 2021 | Led the cannabis pivot; stepped down citing COVID-related ill health |
Nikhyle Dasarath | Executive Director, then CEO | ED from 16 Mar 2021; CEO from 7–8 Jun 2021; Nutritional Foods board from 27 Mar 2022 | Founder and CEO of Ukusekela; honours diploma in software engineering; master-grower training |
Neville Moodley | Executive Director / COO, then Financial Director | Appointed 1 Sep 2020; FD from 28 Mar 2022 | Described as both non-executive and executive in different SENS announcements |
Pieter Watson CA(SA) | Financial Director / CFO | From 22 Apr 2021; succeeded as FD by 28 Mar 2022 | Chartered accountant |
Suzanne Meyer | CFO | 29 Oct 2020 – 28 Feb 2021 | Oversaw the December 2020 interims that were later restated |
Rammalane Monye | Financial Director | Resigned July 2020 | — |
Sashen Nessa Reddy | Executive Director (Financial Manager) | 22 Apr 2021 – 6 Sep 2021 | — |
M.M. Suping | Executive Director; CEO of Nutritional Foods | Through at least 2021 | Bid for Nutritional Foods through Mmabakgosi Properties |
S. (M.S.) Tinawi | Independent NED; chair of Audit & Risk Committee | 2020–2021 | — |
Dr Adel Al Tinawi | NED (Pharmaceutical Development) | 1 Sep 2020 – 10 May 2021 | Pharmacist based in Lyon; master's in clinical evaluation (University of Lyon) |
Tony Kahano Kyubwa | Independent NED | 1 Sep 2020 – 6 Sep 2021 | — |
Boy Manqoba Ngubo | Independent NED; Audit Committee | From 10 May 2021 | Trained at BDO; interim CFO at Joburg Market SOC; NED of PSV Holdings |
Basil Mashabane | Independent NED | From 6 Sep 2021 | Attorney; former Deputy Executive Director, Takeover Regulation Panel; LLB, LLM, MSc |
Igmar Rautenbach CA(SA) | Independent NED | From 28 Mar 2022 | Trained at Ernst & Young; qualified CA in 2001; master's in SA tax; CIMA |
Cobus Kotze | Independent NED | From 28 Mar 2022 | BA LLB (Stellenbosch) |
Thabo Mokgatlha | Non-executive Director | Resigned 1 Sep 2020 | — |
P.M. Chabeli; T. Mashaba; Dr P. Mokgothu | Independent NED; NED; independent NED | Listed in 2020 handbooks | — |
Ian Murgatroyd | Commercial Director | From 25 Apr 2016 | Former Kairos director; 12+ years in pharmaceuticals and FMCG |
John Ellis; Jan Louw | Non-executive Directors | From 12 Jul 2012 | Founding members of E2E and Nutritional Holdings; involved in the listing |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Date |
|---|---|---|
Baphalane Ba Mantserre (printed as "Baphalane Ba Mantserred") | 68.39 | 28 Feb 2019 |
Philisani | 7.28 | 28 Feb 2019 |
Empire Cannabis & Noms | 65.11 | 29 Feb 2020 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning relative to Nutritional Holdings | Latest disclosed revenue |
|---|---|---|---|
Tiger Brands | Staple foods (grains, maize, porridge) | Largest South African food producer; grains division alone had R7.1 billion revenue in FY2025 [S50] | R34.4 billion (FY Sep 2025) [S50] |
RCL Foods | Groceries, baking, sugar, pet food | Broad-line JSE food manufacturer, about 10,500 employees [S51] | R26.5 billion (FY Jun 2025) [S51] |
Libstar Holdings | Ambient and perishable packaged foods, including dry condiments and spices | Mid-cap multi-category FMCG producer | R12.3 billion (FY Dec 2025) [S52] |
PepsiCo South Africa (Pioneer Foods) | Breakfast cereals and porridges | Multinational-owned staple brands | — |
Premier Group | Maize milling, baking | Integrated miller and baker | — |
Nestlé South Africa | Fortified cereals and dairy blends | Multinational with fortified product lines | — |
Labat Africa | Cannabis (Lesotho licences via Zarenka) | Fellow JSE small cap that entered cannabis in 2019 [S16] | — |
Lesotho-licensed medical cannabis producers (several) | Cannabis cultivation and extraction | Competing licence-based export models | — |
South African CBD retail and supplement brands (many) | CBD consumer products | Fragmented retail market | — |
Institutional and school-feeding suppliers | Fortified instant meals | Tender-based competition | — |
Peer Comparison FY2025
| Metric | Nutritional Holdings (FY2020) | Tiger Brands (FY2025) | RCL Foods (FY2025) | Libstar (FY2025) |
|---|---|---|---|---|
Revenue (ZAR Mn) | 40.8 | 34,400 | 26,500 | 12,329 |
Revenue growth (%) | 7.8 | 2.7 | 1.8 | 8.2 |
Profitability margin (%) | 3.1 (operating) | 11.0 (operating, derived) | 9.7 (EBITDA, derived) | 8.7 (normalised EBITDA, derived) |
Recent Developments
Final disclosed newsflow (May 2021 – February 2023): * These are the last 18-plus months of public disclosure.



